Document


Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	FIRST QUARTER
				Percent Change
	2023		2022	Total		Operations	Currency
Sales to customers by
segment of business

Consumer Health
U.S.	$	1,735	1,557	11.4	%	11.4	—
International	2,117		2,029	4.4		11.3	(6.9)
	3,852		3,586	7.4		11.3	(3.9)

Pharmaceutical (1)
U.S.	7,023		6,632	5.9		5.9	—
International	6,390		6,237	2.4		8.6	(6.2)
	13,413		12,869	4.2		7.2	(3.0)

Pharmaceutical excluding COVID-19 Vaccine (1)
U.S.	7,023		6,557	7.1		7.1	—
International	5,643		5,855	(3.6)		2.4	(6.0)
	12,666		12,412	2.0		4.9	(2.9)

MedTech (1)
U.S.	3,759		3,225	16.6		16.6	—
International	3,722		3,746	(0.6)		6.2	(6.8)
	7,481		6,971	7.3		11.0	(3.7)

U.S.	12,517		11,414	9.7		9.7	—
International	12,229		12,012	1.8		8.3	(6.5)
Worldwide	24,746		23,426	5.6		9.0	(3.4)

U.S.	12,517		11,339	10.4		10.4	—
International	11,482		11,630	(1.3)		5.2	(6.5)
Worldwide excluding COVID-19 Vaccine (1)	$	23,999	22,969	4.5	%	7.7	(3.2)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales reconciliation schedule.


Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	FIRST QUARTER

	2023				2022				Percent
				Percent				Percent	Increase
	Amount			to Sales	Amount			to Sales	(Decrease)
Sales to customers	$	24,746		100.0	$	23,426		100.0	5.6
Cost of products sold	8,395			33.9	7,598			32.4	10.5
Gross Profit	16,351			66.1	15,828			67.6	3.3
Selling, marketing and administrative expenses	6,138			24.8	5,938			25.4	3.4
Research and development expense	3,563			14.4	3,462			14.8	2.9
In-process research and development	49			0.2	610			2.6
Interest (income) expense, net	(20)			(0.1)	(12)			(0.1)
Other (income) expense, net	7,228			29.2	(102)			(0.4)
Restructuring	130			0.6	70			0.3
Earnings/(Loss) before provision for taxes on income	(737)			(3.0)	5,862			25.0	(112.6)
Provision for/(Benefit from) taxes on income	(669)			(2.7)	713			3.0	(193.8)
Net earnings/(Loss)	$	(68)		(0.3)	$	5,149		22.0	(101.3)

Net earnings/(Loss) per share (Basic/Diluted)*	$	(0.03)			$	1.93			(101.6)

Average shares outstanding (Basic/Diluted)*	2,605.5				2,666.5

Effective tax rate	90.8		%		12.2		%

Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income	$	8,468		34.2	$	8,218		35.1	3.0
Net earnings	$	7,068		28.6	$	7,129		30.4	(0.9)
Net earnings per share (Diluted)	$	2.68			$	2.67			0.4
Average shares outstanding (Diluted)**	2,634.3				2,666.5
Effective tax rate	16.5		%		13.3		%

* Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutive.

** Difference of 28.8 shares due to anti-dilutive impact on net loss position.

(1) See Reconciliation of Non-GAAP Financial Measures.

(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.


Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

		First Quarter
	(Dollars in Millions Except Per Share Data)	2023		2022
	Net Earnings/(Loss), after tax- as reported	$	(68)	$	5,149

	Pre-tax Adjustments
	Litigation expense	6,900		-
	Intangible Asset Amortization expense	1,204		1,108
	COVID-19 Vaccine related costs1	444		-
	Consumer Health separation costs	300		102
	Restructuring related2	130		72
	(Gains)/losses on securities	72		411
	Medical Device Regulation3	64		60
	IPR&D	49		610
	Acquisition, integration and divestiture related	42		-
	Other	-		(7)

	Tax Adjustments
	Tax impact on special item adjustments 4	(2,057)		(393)
	Consumer Health separation tax related costs	11		96
	Tax legislation and other tax related	(23)		(79)
	Adjusted Net Earnings, after tax	$	7,068	$	7,129
	Average shares outstanding (Diluted)	2,634.3		2,666.5
	Adjusted net earnings per share (Diluted)	$	2.68	$	2.67
	Operational adjusted net earnings per share (Diluted)	$	2.75

	Notes:
1	COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments.
2	In the first quarter of 2023, the company completed a prioritization of its research and development (R&D) investment within the Pharmaceutical segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, HIV and hepatitis. The restructuring expenses of $130 million in the quarter include the termination of partnered and non-partnered program costs and asset impairments.
3	European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024.
4	The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.


Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth (A)
FIRST QUARTER 2023 ACTUAL vs. 2022 ACTUAL

Segments
	Consumer Health		Pharmaceutical		MedTech		Total
WW As Reported	7.4	%	4.2	%	7.3	%	5.6	%
U.S.	11.4	%	5.9	%	16.6	%	9.7	%
International	4.4	%	2.4	%	(0.6)	%	1.8	%

WW Currency	(3.9)		(3.0)		(3.7)		(3.4)
U.S.	—		—		—		—
International	(6.9)		(6.2)		(6.8)		(6.5)

WW Operational	11.3	%	7.2	%	11.0	%	9.0	%
U.S.	11.4	%	5.9	%	16.6	%	9.7	%
International	11.3	%	8.6	%	6.2	%	8.3	%

Abiomed					(4.6)		(1.4)
U.S.					(8.2)		(2.3)
International					(1.6)		(0.5)

All Other Acquisitions and Divestitures	0.0		0.0		0.0		0.0
U.S.	0.0		0.0		0.0		0.0
International	0.0		0.2		0.0		0.1

WW Adjusted Operational	11.3	%	7.2	%	6.4	%	7.6	%
U.S.	11.4	%	5.9	%	8.4	%	7.4	%
International	11.3	%	8.8	%	4.6	%	7.9	%

Note: Percentages are based on actual, non-rounded figures and may not sum

(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.


Johnson & Johnson
Segment Sales
(Dollars in Millions)


		FIRST QUARTER
				% Change
		2023	2022	Reported		Operational (1)		Currency
CONSUMER HEALTH SEGMENT (2)

OTC
US	$	745	670	11.0	%	11.0	%	—	%
Intl		897	791	13.5		19.8		(6.3)
WW		1,642	1,461	12.4		15.8		(3.4)

SKIN HEALTH / BEAUTY
US		617	544	13.4		13.4		—
Intl		493	468	5.3		12.6		(7.3)
WW		1,110	1,012	9.7		13.1		(3.4)

ORAL CARE
US		159	143	11.6		11.6		—
Intl		202	223	(9.6)		(4.0)		(5.6)
WW		361	366	(1.3)		2.1		(3.4)

BABY CARE
US		96	85	13.0		13.0		—
Intl		263	270	(2.8)		4.5		(7.3)
WW		359	355	1.0		6.5		(5.5)

WOMEN'S HEALTH
US		3	3	1.8		1.8		—
Intl		214	224	(4.9)		4.1		(9.0)
WW		217	228	(4.8)		4.1		(8.9)

WOUND CARE / OTHER
US		115	112	2.6		2.6		—
Intl		49	52	(6.0)		2.3		(8.3)
WW		164	164	(0.1)		2.5		(2.6)

TOTAL CONSUMER HEALTH
US		1,735	1,557	11.4		11.4		—
Intl		2,117	2,029	4.4		11.3		(6.9)
WW	$	3,852	3,586	7.4	%	11.3	%	(3.9)	%

See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)

		FIRST QUARTER
				% Change
		2023	2022	Reported		Operational (1)		Currency
PHARMACEUTICAL SEGMENT (2) (3)

IMMUNOLOGY
US	$	2,448	2,501	(2.1)	%	(2.1)	%	—	%
Intl		1,664	1,617	2.9		9.7		(6.8)
WW		4,112	4,119	(0.2)		2.5		(2.7)
REMICADE
US		276	358	(22.8)		(22.8)		—
US Exports (4)		41	80	(48.8)		(48.8)		—
Intl		170	225	(24.4)		(20.0)		(4.4)
WW		487	663	(26.5)		(25.0)		(1.5)
SIMPONI / SIMPONI ARIA
US		271	287	(5.6)		(5.6)		—
Intl		266	283	(6.1)		1.8		(7.9)
WW		537	571	(5.8)		(1.9)		(3.9)
STELARA
US		1,451	1,379	5.2		5.2		—
Intl		993	909	9.3		16.2		(6.9)
WW		2,444	2,288	6.8		9.6		(2.8)
TREMFYA
US		406	391	3.9		3.9		—
Intl		234	199	17.3		24.9		(7.6)
WW		640	590	8.4		11.0		(2.6)
OTHER IMMUNOLOGY
US		3	6	(51.2)		(51.2)		—
Intl		0	0	—		—		—
WW		3	6	(51.3)		(51.3)		0.0

INFECTIOUS DISEASES
US		392	461	(14.9)		(14.9)		—
Intl		1,193	836	42.8		49.2		(6.4)
WW		1,586	1,297	22.3		26.4		(4.1)
COVID-19 VACCINE
US		0	75	*		*		—
Intl		747	382	95.6		*		(8.9)
WW		747	457	63.4		70.8		(7.4)
EDURANT / rilpivirine
US		9	9	(1.4)		(1.4)		—
Intl		271	239	13.4		18.7		(5.3)
WW		280	248	12.8		18.0		(5.2)
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US		378	369	2.5		2.5		—
Intl		99	132	(25.2)		(21.2)		(4.0)
WW		477	501	(4.8)		(3.7)		(1.1)
OTHER INFECTIOUS DISEASES
US		5	8	(33.1)		(33.1)		—
Intl		77	83	(7.6)		(5.6)		(2.0)
WW		82	91	(9.8)		(8.0)		(1.8)

See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)

		FIRST QUARTER
				% Change
		2023	2022	Reported	Operational (1)	Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)

NEUROSCIENCE
US	$	978	843	16.0%	16.0%	—%
Intl		826	898	(8.1)	(3.1)	(5.0)
WW		1,804	1,741	3.6	6.1	(2.5)
CONCERTA / methylphenidate
US		70	35	*	*	—
Intl		136	122	11.4	20.2	(8.8)
WW		206	157	31.4	38.2	(6.8)
INVEGA SUSTENNA / XEPLION / INVEGA
TRINZA / TREVICTA
US		713	661	7.9	7.9	—
Intl		331	387	(14.6)	(8.9)	(5.7)
WW		1,044	1,048	(0.4)	1.7	(2.1)
SPRAVATO
US		111	61	82.4	82.4	—
Intl		20	9	*	*	*
WW		131	70	86.9	88.0	(1.1)
OTHER NEUROSCIENCE
US		84	86	(3.5)	(3.5)	—
Intl		339	380	(10.7)	(7.6)	(3.1)
WW		423	467	(9.4)	(6.9)	(2.5)

ONCOLOGY
US		1,889	1,582	19.4	19.4	—
Intl		2,223	2,369	(6.1)	(0.1)	(6.0)
WW		4,112	3,950	4.1	7.7	(3.6)
CARVYKTI
US		70	—	*	*	—
Intl		2	—	*	*	—
WW		72	—	*	*	—
DARZALEX
US		1,191	953	25.0	25.0	—
Intl		1,072	903	18.8	26.4	(7.6)
WW		2,264	1,856	22.0	25.7	(3.7)
ERLEADA
US		249	206	21.2	21.2	—
Intl		293	194	50.9	60.7	(9.8)
WW		542	400	35.6	40.3	(4.7)
IMBRUVICA
US		270	370	(27.1)	(27.1)	—
Intl		557	668	(16.6)	(11.7)	(4.9)
WW		827	1,038	(20.3)	(17.2)	(3.1)
ZYTIGA / abiraterone acetate
US		16	19	(14.0)	(14.0)	—
Intl		229	520	(56.0)	(52.2)	(3.8)
WW		245	539	(54.5)	(50.9)	(3.6)
OTHER ONCOLOGY
US		92	34	*	*	—
Intl		70	84	(17.2)	(12.1)	(5.1)
WW		162	118	37.4	41.0	(3.6)

See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)


		FIRST QUARTER
				% Change
		2023	2022	Reported		Operational (1)		Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)

PULMONARY HYPERTENSION
US	$	600	572	4.9	%	4.9	%	—	%
Intl		272	279	(2.7)		5.3		(8.0)
WW		872	852	2.4		5.0		(2.6)
OPSUMIT
US		273	273	(0.1)		(0.1)		—
Intl		167	170	(1.6)		6.1		(7.7)
WW		440	443	(0.7)		2.3		(3.0)
UPTRAVI
US		304	269	13.1		13.1		—
Intl		58	56	3.3		9.4		(6.1)
WW		362	325	11.4		12.4		(1.0)
OTHER PULMONARY HYPERTENSION
US		23	30	(22.4)		(22.4)		—
Intl		47	53	(12.6)		(1.8)		(10.8)
WW		70	83	(16.1)		(9.3)		(6.8)

CARDIOVASCULAR / METABOLISM / OTHER
US		715	672	6.3		6.3		—
Intl		212	238	(10.8)		(6.3)		(4.5)
WW		927	910	1.8		3.0		(1.2)
XARELTO
US		578	508	13.7		13.7		—
Intl		—	—	—		—		—
WW		578	508	13.7		13.7		—








OTHER
US		137	164	(16.7)		(16.7)		—
Intl		212	238	(10.8)		(6.3)		(4.5)
WW		349	402	(13.2)		(10.5)		(2.7)

TOTAL PHARMACEUTICAL
US		7,023	6,632	5.9		5.9		—
Intl		6,390	6,237	2.4		8.6		(6.2)
WW	$	13,413	12,869	4.2	%	7.2	%	(3.0)	%

See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)

		FIRST QUARTER
				% Change
		2023	2022	Reported		Operational (1)		Currency
MEDTECH SEGMENT (2) (3)

INTERVENTIONAL SOLUTIONS
US	$	863	494	74.5	%	74.5	%	—	%
Intl		640	597	7.1		14.9		(7.8)
WW		1,503	1,092	37.6		41.9		(4.3)

ELECTROPHYSIOLOGY
US		571	470	21.4		21.4		—
Intl		522	532	(1.8)		6.1		(7.9)
WW		1,092	1,002	9.1		13.3		(4.2)

ABIOMED
US		264	—	*		*		—
Intl		60	—	*		*		—
WW		324	—	*		*		—

OTHER INTERVENTIONAL SOLUTIONS
US		28	24	17.4		17.4		—
Intl		58	65	(11.7)		(5.0)		(6.7)
WW		87	90	(3.9)		1.1		(5.0)

ORTHOPAEDICS
US		1,363	1,289	5.8		5.8		—
Intl		881	899	(2.0)		4.0		(6.0)
WW		2,245	2,188	2.6		5.1		(2.5)

HIPS
US		241	225	7.3		7.3		—
Intl		149	164	(9.0)		(3.6)		(5.4)
WW		390	389	0.4		2.7		(2.3)

KNEES
US		226	201	12.4		12.4		—
Intl		142	138	3.4		9.6		(6.2)
WW		368	339	8.7		11.3		(2.6)

TRAUMA
US		491	475	3.2		3.2		—
Intl		267	273	(2.4)		3.6		(6.0)
WW		757	748	1.2		3.4		(2.2)

SPINE, SPORTS & OTHER
US		406	387	4.7		4.7		—
Intl		323	324	(0.3)		5.9		(6.2)
WW		729	712	2.4		5.2		(2.8)

See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)

		FIRST QUARTER
				% Change
		2023	2022	Reported		Operational (1)		Currency
MEDTECH SEGMENT (2) (3) (Continued)

SURGERY
US	$	975	921	5.9	%	5.9	%	—	%
Intl		1,459	1,513	(3.6)		3.1		(6.7)
WW		2,434	2,434	0.0		4.1		(4.1)

ADVANCED
US		444	417	6.5		6.5		—
Intl		673	729	(7.6)		(1.1)		(6.5)
WW		1,118	1,146	(2.5)		1.6		(4.1)

GENERAL
US		531	504	5.4		5.4		—
Intl		785	784	0.2		7.0		(6.8)
WW		1,316	1,288	2.2		6.4		(4.2)

VISION
US		558	521	7.1		7.1		—
Intl		743	736	0.8		8.0		(7.2)
WW		1,300	1,257	3.4		7.6		(4.2)

CONTACT LENSES / OTHER
US		444	400	11.1		11.1		—
Intl		509	511	(0.3)		7.9		(8.2)
WW		953	910	4.7		9.3		(4.6)
SURGICAL
US		114	121	(6.0)		(6.0)		—
Intl		233	226	3.3		8.0		(4.7)
WW		347	347	0.1		3.1		(3.0)

TOTAL MEDTECH
US		3,759	3,225	16.6		16.6		—
Intl		3,722	3,746	(0.6)		6.2		(6.8)
WW	$	7,481	6,971	7.3	%	11.0	%	(3.7)	%


See footnotes at end of schedule

Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-
rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures; refer to supplemental sales schedules
(4) Reported as U.S. sales


Supplemental Sales Reconciliation (Unaudited)
(Dollars in Millions)

		FIRST QUARTER
					Percent Change
		2023		2022	Total		Operations	Currency

	Pharmaceutical
	U.S.	$	7,023	6,632	5.9	%	5.9	-
	International	6,390		6,237	2.4		8.6	(6.2)
	Worldwide	13,413		12,869	4.2		7.2	(3.0)

	COVID-19 Vaccine
	U.S.	0		75	*		*	-
	International	747		382	95.6		*	(8.9)
	Worldwide	747		457	63.4		70.8	(7.4)

	Pharmaceutical excluding COVID-19 Vaccine
	U.S.	7,023		6,557	7.1		7.1	-
	International	5,643		5,855	(3.6)		2.4	(6.0)
	Worldwide	12,666		12,412	2.0		4.9	(2.9)

	Worldwide
	U.S.	12,517		11,414	9.7		9.7	-
	International	12,229		12,012	1.8		8.3	(6.5)
	Worldwide	24,746		23,426	5.6		9.0	(3.4)

	COVID-19 Vaccine
	U.S.	0		75	*		*	-
	International	747		382	95.6		*	(8.9)
	Worldwide	747		457	63.4		70.8	(7.4)

	Worldwide
	U.S.	12,517		11,339	10.4		10.4	-
	International	11,482		11,630	(1.3)		5.2	(6.5)
	Worldwide excluding COVID-19 Vaccine	$	23,999	22,969	4.5	%	7.7	(3.2)


	Note: Columns and rows within tables may not add due to rounding

	* Percentage greater than 100% or not meaningful


Johnson & Johnson
Supplemental Sales Information
(Dollars in Millions)
Certain prior year amounts have been reclassified to
conform to current year product disclosures
	2021		2022				2022
	Full Year		Q1	Q2	Q3	Q4	Full Year
PHARMACEUTICAL SEGMENT (1)
NEUROSCIENCE (2)
SPRAVATO
US	$	198	61	74	88	105	328
INTL	26		9	11	12	14	46
WW	224		70	85	100	119	374
OTHER NEUROSCIENCE (2)
US	427		86	93	106	91	376
Intl	1,647		380	341	286	351	1,358
WW	2,074		467	433	393	442	1,734
ONCOLOGY
CARVYKTI
US	—		—	24	55	54	133
INTL	—		—	—	—	—	—
WW	—		—	24	55	54	133
OTHER ONCOLOGY
US	110		34	33	37	52	156
INTL	458		84	72	64	63	283
WW	568		118	106	100	114	438
CARDIOVASCULAR / METABOLISM / OTHER
OTHER (3)
US	754		164	148	147	110	569
INTL	927		238	215	198	194	845
WW	1,682		402	363	345	304	1,414

MEDTECH SEGMENT (1)
INTERVENTIONAL SOLUTIONS
ELECTROPHYSIOLOGY	1,730		470	499	520	547	2,036
US	1,893		532	469	453	447	1,901
INTL	3,623		1,002	968	973	994	3,937
WW
ABIOMED (4)
US	—		—	—	—	31	31
INTL	—		—	—	—	—	—
WW	—		—	—	—	31	31
OTHER INTERVENTIONAL SOLUTIONS
US	106		24	26	27	25	102
Intl	242		65	56	60	48	230
WW	$	348	90	81	87	73	332

Note: Columns and rows within tables may not add due to rounding.

(1) Unaudited
(2) Other Neuroscience is inclusive of RISPERDAL CONSTA, which was previously disclosed separately
(3) Other is inclusive of INVOKANA, which was previously disclosed separately
(4) Acquired on December 22, 2022